{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T08:03:41Z","timestamp":1790496221298,"version":"4.1.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T00:00:00Z","timestamp":1605830400000},"content-version":"am","delay-in-days":355,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.revmed.2019.07.016","type":"journal-article","created":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T08:56:07Z","timestamp":1572857767000},"page":"816-825","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Les inhibiteurs de JAK\u00a0: perspectives pour la m\u00e9decine interne"],"prefix":"10.1016","volume":"40","author":[{"given":"T.","family":"El Jammal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Gerfaud-Valentin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3070-3842","authenticated-orcid":false,"given":"P.","family":"S\u00e8ve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5249-3650","authenticated-orcid":false,"given":"Y.","family":"Jamilloux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2019.07.016_bib0305","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40259-019-00333-w","article-title":"Selective JAKinibs:Prospects in Inflammatory and Autoimmune Diseases","volume":"33","author":"Virtanen","year":"2019","journal-title":"BioDrugs"},{"key":"10.1016\/j.revmed.2019.07.016_bib0310","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"16","author":"Schwartz","year":"2017","journal-title":"Nat Rev Drug Discovery"},{"key":"10.1016\/j.revmed.2019.07.016_bib0315","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","article-title":"JAK\u2013STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects","volume":"77","author":"Banerjee","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.revmed.2019.07.016_bib0320","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/acr.20494","article-title":"Tofacitinib Study Investigators Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate","volume":"63","author":"Tanaka","year":"2011","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.revmed.2019.07.016_bib0325","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1056\/NEJMoa1112072","article-title":"Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis","volume":"367","author":"van Vollenhoven","year":"2012","journal-title":"New Engl J Med"},{"key":"10.1016\/j.revmed.2019.07.016_bib0330","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","article-title":"Tofacitinib versus Methotrexate in Rheumatoid Arthritis","volume":"370","author":"Lee","year":"2014","journal-title":"New Engl J Med"},{"key":"10.1016\/j.revmed.2019.07.016_bib0335","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","article-title":"Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial","volume":"390","author":"Fleischmann","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2019.07.016_bib0340","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1056\/NEJMoa1112168","article-title":"Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis","volume":"367","author":"Sandborn","year":"2012","journal-title":"New Engl J Med"},{"key":"10.1016\/j.revmed.2019.07.016_bib0345","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis","author":"Sandborn","year":"2017","journal-title":"New Engl J Med"},{"key":"10.1016\/j.revmed.2019.07.016_bib0350","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/j.1365-2133.2012.11168.x","article-title":"Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study: Tofacitinib improves the clinical signs of psoriasis","volume":"167","author":"Papp","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.revmed.2019.07.016_bib0355","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jaad.2016.01.013","article-title":"Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2\u00a0randomized phase-III studies and 1\u00a0open-label long-term extension study","volume":"74","author":"Papp","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.revmed.2019.07.016_bib0360","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/annrheumdis-2016-210322","article-title":"Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2019.07.016_bib0365","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1016\/j.jaad.2017.12.019","article-title":"Emerging therapies for atopic dermatitis: JAK inhibitors","volume":"78","author":"Cotter","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.revmed.2019.07.016_bib0370","first-page":"1","article-title":"Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata","author":"Kennedy Crispin","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.revmed.2019.07.016_bib0375","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.autrev.2017.11.009","article-title":"Targeting interferons and their pathways in systemic lupus erythematosus","volume":"17","author":"Chasset","year":"2018","journal-title":"Autoimmunity Reviews"},{"key":"10.1016\/j.revmed.2019.07.016_bib0380","first-page":"5","volume":"302","author":"Changelian","year":"2003"},{"key":"10.1016\/j.revmed.2019.07.016_bib0385","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/art.33419","article-title":"A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone","volume":"64","author":"Kremer","year":"2012","journal-title":"Arthritis & Rheumatism"},{"key":"10.1016\/j.revmed.2019.07.016_bib0390","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis","volume":"376","author":"Taylor","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2019.07.016_bib0395","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1016\/S0140-6736(18)31115-2","article-title":"Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3\u00a0trial","volume":"391","author":"Burmester","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2019.07.016_bib0400","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1016\/S0140-6736(18)31116-4","article-title":"Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3\u00a0trial","volume":"391","author":"Genovese","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2019.07.016_bib0405","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1136\/annrheumdis-2016-210104","article-title":"Filgotinib (GLPG0634\/GS-6034), an oral JAK1\u00a0selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1)","volume":"76","author":"Westhovens","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2019.07.016_bib0410","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1136\/annrheumdis-2016-210105","article-title":"Filgotinib (GLPG0634\/GS-6034), an oral selective JAK1\u00a0inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2)","volume":"76","author":"Kavanaugh","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2019.07.016_bib0415","first-page":"8","article-title":"Inhibiting ex-vivo Th17\u00a0responses in Ankylosing Spondylitis by targeting Janus kinases","author":"Hammitzsch","year":"2018","journal-title":"Scientific Reports"},{"key":"10.1016\/j.revmed.2019.07.016_bib0420","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jfma.2018.02.001","article-title":"Janus kinase-1\u00a0and 3\u00a0in ankylosing spondylitis","volume":"118","author":"Liao","year":"2019","journal-title":"J Formosan Med Assoc"},{"key":"10.1016\/j.revmed.2019.07.016_bib0425","doi-asserted-by":"crossref","first-page":"e163","DOI":"10.1038\/cti.2017.49","article-title":"Progress of genome-wide association studies of ankylosing spondylitis","volume":"6","author":"Li","year":"2017","journal-title":"Clin Transl Immunol"},{"key":"10.1016\/j.revmed.2019.07.016_bib0430","doi-asserted-by":"crossref","first-page":"e11149","DOI":"10.1097\/MD.0000000000011149","article-title":"Case report: successful treatment of refractory SAPHO syndrome with the JAK inhibitor tofacitinib","volume":"97","author":"Yang","year":"2018","journal-title":"Medicine"},{"key":"10.1016\/j.revmed.2019.07.016_bib0435","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/BOR.0000000000000069","article-title":"The interleukin-23\/interleukin-17\u00a0immune axis as a promising new target in the treatment of spondyloarthritis","volume":"26","author":"Yeremenko","year":"2014","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.revmed.2019.07.016_bib0440","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s12026-013-8481-0","article-title":"JAK\/STAT\/PKC\u03b4 molecular pathways in synovial fluid T lymphocytes reflect the in vivo T helper-17\u00a0expansion in psoriatic arthritis","volume":"58","author":"Fiocco","year":"2014","journal-title":"Immunol Res"},{"key":"10.1016\/j.revmed.2019.07.016_bib0445","doi-asserted-by":"crossref","first-page":"e000806","DOI":"10.1136\/rmdopen-2018-000806","article-title":"Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden\u2014a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs","volume":"5","author":"Strand","year":"2019","journal-title":"RMD Open"},{"key":"10.1016\/j.revmed.2019.07.016_bib0450","doi-asserted-by":"crossref","first-page":"e000808","DOI":"10.1136\/rmdopen-2018-000808","article-title":"Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond","volume":"5","author":"Strand","year":"2019","journal-title":"RMD Open"},{"key":"10.1016\/j.revmed.2019.07.016_bib0455","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/bjd.14018","article-title":"Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials","volume":"173","author":"Papp","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.revmed.2019.07.016_bib0460","doi-asserted-by":"crossref","first-page":"e84450","DOI":"10.1371\/journal.pone.0084450","article-title":"Association of STAT4\u00a0Polymorphism with Severe Renal Insufficiency in Lupus Nephritis","volume":"8","author":"Bolin","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.revmed.2019.07.016_bib0465","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1177\/0961203306075383","article-title":"Activation of the STAT1\u00a0signalling pathway in lupus nephritis in MRL\/lpr mice","volume":"16","author":"Dong","year":"2007","journal-title":"Lupus"},{"key":"10.1016\/j.revmed.2019.07.016_bib0470","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1177\/0961203310367660","article-title":"Jak\/STAT signaling is involved in the inflammatory infiltration of the kidneys in MRL\/lpr mice","volume":"19","author":"Wang","year":"2010","journal-title":"Lupus"},{"key":"10.1016\/j.revmed.2019.07.016_bib0475","first-page":"18","article-title":"JAK3-STAT pathway blocking benefits in experimental lupus nephritis","author":"Ripoll","year":"2016","journal-title":"Arthr Res Ther"},{"key":"10.1016\/j.revmed.2019.07.016_bib0480","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2019-215455","article-title":"Successful treatment of arthritis and rash with tofacitinib in systemic lupus erythematosus: the experience from a single centre","author":"You","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2019.07.016_bib0485","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1038\/jid.2015.107","article-title":"Ruxolitinib Attenuates Cutaneous Lupus Development in a Mouse Lupus Model","volume":"135","author":"Chan","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.revmed.2019.07.016_bib0490","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.jid.2016.02.015","article-title":"JAK1\/2\u00a0Inhibitor Ruxolitinib Controls a Case of Chilblain Lupus Erythematosus","volume":"136","author":"Wenzel","year":"2016","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.revmed.2019.07.016_bib0495","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1177\/0961203316640910","article-title":"Safety, tolerability, efficacy and pharmacodynamics of the selective JAK1\u00a0inhibitor GSK2586184\u00a0in patients with systemic lupus erythematosus","volume":"25","author":"Kahl","year":"2016","journal-title":"Lupus"},{"key":"10.1016\/j.revmed.2019.07.016_bib0500","doi-asserted-by":"crossref","first-page":"191","DOI":"10.7150\/ijms.17718","article-title":"Reviewing primary Sj\u00f6gren's syndrome: beyond the dryness - From pathophysiology to diagnosis and treatment","volume":"14","author":"Both","year":"2017","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.revmed.2019.07.016_bib0505","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1002\/art.40040","article-title":"Genome-Wide Association Analysis Reveals Genetic Heterogeneity of Sj\u00f6gren's Syndrome According to Ancestry","volume":"69","author":"Taylor","year":"2017","journal-title":"Arthr Rheumatol"},{"key":"10.1016\/j.revmed.2019.07.016_bib0510","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.clim.2017.04.018","article-title":"Genetics of Sj\u00f6gren's syndrome","volume":"182","author":"Teos","year":"2017","journal-title":"Clin Immunol"},{"key":"10.1016\/j.revmed.2019.07.016_bib0515","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/j.ophtha.2012.03.017","article-title":"Immunomodulatory effect of the topical ophthalmic Janus Kinase inhibitor Tofacitinib (CP-690,550) in patients with dry eye disease","volume":"119","author":"Huang","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.revmed.2019.07.016_bib0520","first-page":"183","article-title":"Physiopathologie de la scl\u00e9rodermie syst\u00e9mique","volume":"32","author":"Allanore","year":"2016"},{"key":"10.1016\/j.revmed.2019.07.016_bib0525","doi-asserted-by":"crossref","first-page":"4302","DOI":"10.1074\/jbc.M116.773085","article-title":"Transforming Growth Factor-\u03b2 (TGF-\u03b2) directly activates the JAK1-STAT3\u00a0axis to induce hepatic fibrosis in coordination with the SMAD pathway","volume":"292","author":"Tang","year":"2017","journal-title":"J Biol Chem"},{"key":"10.1016\/j.revmed.2019.07.016_bib0530","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1111\/jdv.14876","article-title":"The use of JAK inhibitors in the treatment of progressive systemic sclerosis","volume":"32","author":"Deverapalli","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.revmed.2019.07.016_bib0535","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1080\/03009742.2017.1387673","article-title":"Tofacitinib rapidly ameliorated polyarthropathy in a patient with systemic sclerosis","volume":"47","author":"Komai","year":"2018","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.revmed.2019.07.016_bib0540","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1111\/ijd.14064","article-title":"JAK-STAT signaling pathway inhibition: a role for treatment of discoid lupus erythematosus and dermatomyositis","volume":"57","author":"Kahn","year":"2018","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.revmed.2019.07.016_bib0545","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1007\/s00393-018-0565-8","article-title":"Ansprechen einer Dermatomyositis mit Lungenbeteiligung auf eine Januskinase-Inhibitor-Therapie","volume":"77","author":"Hornig","year":"2018","journal-title":"Zeitschrift f\u00fcr Rheumatologie"},{"key":"10.1016\/j.revmed.2019.07.016_bib0600","series-title":"Study of tofacitinib in refractory dermatomyositis (STIR): an open label pilot study in refractory dermatomyositis","author":"Paik","year":"2018"},{"key":"10.1016\/j.revmed.2019.07.016_bib0555","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3748\/wjg.v20.i1.91","article-title":"Inflammatory bowel disease: Pathogenesis","volume":"20","author":"Zhang","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.revmed.2019.07.016_bib0560","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1136\/gutjnl-2016-312735","article-title":"Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials","volume":"66","author":"Pan\u00e9s","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.revmed.2019.07.016_bib0565","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/sji.12211","article-title":"Differential Expression of Suppressor of Cytokine Signalling Proteins in Beh\u00e7et's Disease","volume":"80","author":"Hamedi","year":"2014","journal-title":"Scand J Immunol"},{"issue":"5","key":"10.1016\/j.revmed.2019.07.016_bib0605","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1136\/annrheumdis-2017-212403","article-title":"A20 haploinsufficiency (HA20): clinical phenotypes and disease course of patients with a newly recognised NF-kB-mediated autoinflammatory disease","volume":"77","author":"Aeschlimann","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.revmed.2019.07.016_bib0610","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2018-2845","article-title":"Tofacitinib treatment of refractory systemic juvenile idiopathic arthritis","volume":"143","author":"Huang","year":"2019","journal-title":"Pediatrics"},{"issue":"5","key":"10.1016\/j.revmed.2019.07.016_bib0615","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.25063","article-title":"Ruxolitinib as first-line treatment in secondary hemophagocytic lymphohistiocytosis: a second experience","volume":"93","author":"Zandvakili","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.revmed.2019.07.016_bib0585","first-page":"7","article-title":"Identification of Jak-STAT signaling involvement in sarcoidosis severity via a novel microRNA-regulated peripheral blood mononuclear cell gene signature","author":"Zhou","year":"2017","journal-title":"Scientific Reports"},{"key":"10.1016\/j.revmed.2019.07.016_bib0590","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2019-215387","article-title":"Refractory sarcoidosis-like systemic granulomatosis responding to ruxolitinib","author":"Levraut","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2019.07.016_bib0595","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s40123-019-0171-0","article-title":"Reviewing the pathophysiology behind the advances in the management of giant cell arteritis","volume":"8","author":"Al-Mousawi","year":"2019","journal-title":"Ophthalmol Ther"},{"key":"10.1016\/j.revmed.2019.07.016_bib0300","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1161\/CIRCULATIONAHA.117.030423","article-title":"Inhibition of JAK-STAT Signaling Suppresses Pathogenic Immune Responses in Medium and Large Vessel Vasculitis","volume":"137","author":"Zhang","year":"2018","journal-title":"Circulation"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866319306174?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866319306174?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:41:15Z","timestamp":1759336875000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866319306174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":60,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S0248866319306174"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2019.07.016","relation":{},"ISSN":["0248-8663"],"issn-type":[{"value":"0248-8663","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Les inhibiteurs de JAK\u00a0: perspectives pour la m\u00e9decine interne","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2019.07.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI).","name":"copyright","label":"Copyright"}]}}